靶向治疗在胸腺癌中的价值

Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. 

胸腺癌是一种罕见的肿瘤性病变，可以通过其侵袭性和不良预后与良性胸腺瘤区分开来。 美国国家综合癌症网络指南推荐对可切除的肿瘤在术后进行铂类化疗辅助治疗。

However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. 

然而，转移性或复发性胸腺癌的预后很差，尚无具有一致性益处的治疗方案。 此外，这些肿瘤的相对罕见使临床试验变得困难。胸腺瘤的分子分析显示基因突变的高发生率和靶向治疗的前景。

We will briefly outline and review the current role of targeted therapy in thymic cancer.

我们将简要概述和综述目前靶向治疗在胸腺癌中的价值。